Actinogen Medical Secures $11.1M for Alzheimer’s Research
Company Announcements

Actinogen Medical Secures $11.1M for Alzheimer’s Research

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited has announced the oversubscription of its $3.0 million share purchase plan, raising a total of $11.1 million to fund its continued research into neurological treatments. The capital will support the enrollment of patients in the XanaMIA Phase 2b/3 trial for Alzheimer’s Disease, extending the company’s cash runway until late CY26. New shares and options will be issued upon shareholder approval at the upcoming EGM, with the options listed on the ASX for trading.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Secures $9 Million R&D Rebate Boost
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Updates Director’s Securities Holdings
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Expands Shares Amid Drug Development Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App